Indication
Residual
5 clinical trials
6 products
Clinical trial
An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade MeningiomaStatus: Recruiting, Estimated PCD: 2025-09-30
Product
NEO100Clinical trial
Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy TrialsStatus: Completed, Estimated PCD: 2016-12-26
Product
DinutuximabClinical trial
A Blinded Randomized Study of Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients (≥ 75 Years)Status: Recruiting, Estimated PCD: 2024-10-01
Product
neostigmine/glycopyrrolateProduct
SugammadexClinical trial
Diaphragm and Lung Ultrasound After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children Undergoing Surgery : A Randomized Double-blind Controlled TrialStatus: Recruiting, Estimated PCD: 2025-02-15
Product
NeostigmineClinical trial
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade GliomasStatus: Not yet recruiting, Estimated PCD: 2026-05-31
Product
5-Aminolevulinic Acid